BCL2 and acute myeloid leukemia: For these reasons, consideration should also be given to identifying the biologic subtypes of AML most likely to benefit from a given combination, as illustrated by the suggestion that basal Akt activation might predict for efficacy of a strategy simultaneously targeting Bcl-2/-xL nd PI3K/mTOR.